Ginkgo Bioworks Holdings ROE 2020-2023 | DNA

Current and historical return on equity (ROE) values for Ginkgo Bioworks Holdings (DNA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Ginkgo Bioworks Holdings ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2023-03-31 $-1.72B $1.61B -108.33%
2022-12-31 $-2.11B $1.74B -132.52%
2022-09-30 $-3.53B $1.44B -228.18%
2022-06-30 $-2.96B $1.57B -186.18%
2022-03-31 $-2.35B $1.61B -195.50%
2021-12-31 $-1.83B $1.57B -229.23%
2021-06-30 $-0.15B $0.01B -6160.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.379B $0.478B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.584B 22.35
Arcus Biosciences (RCUS) United States $1.536B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.191B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00